Homocysteine: a new cardiac risk factor?
- PMID: 11195611
- PMCID: PMC6655194
- DOI: 10.1002/clc.4960240113
Homocysteine: a new cardiac risk factor?
Abstract
Elevated plasma homocysteine levels have recently been implicated as a new risk factor for coronary artery disease. In this article, homocysteine metabolism, secondary causes of elevated plasma homocysteine, and the potential mechanism of vascular damage in hyperhomocysteinemia are briefly reviewed. The current clinical evidence implicating hyperhomocysteinemia as a risk factor for coronary artery disease, as well as the data regarding the effects of B vitamin supplementation on homocysteine concentrations, are also reviewed. The current recommendation of the authors is to treat patients with known coronary artery disease or those who are considered to be at high risk for coronary artery disease with 400 microg of folate supplementation. Until prospective clinical trial data become available, this approach appears to be a safe and effective way to approach this patient population.
References
-
- Selhub J, Jacques PF, Bostom AG: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993; 270: 2693–2698 - PubMed
-
- McCully KS: Chemical pathology of homocysteine III. Cellular function and aging. Ann Clin Lab Sci 1994; 24: 134–152 - PubMed
-
- Verhoef P, Stampfer MJ, Buring JE: Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B6, B12 and folate. Am J Epidemiol 1996; 143: 845–859 - PubMed
-
- Naurath HJ, Joosten E, Riezler R: Effects of Vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346: 85–89 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
